Product Name: CK2a1 (252-258) pY255
Product Number: PE-04AJZ95
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: CK2a1 (252-258) pY255

Product Use: Services as a blocking peptide for use with the CK2a-pY255 rabbit polyclonal antibody (Cat. No.: AB-PK582) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the last quarter of the kinase catalytic domain. This is the major in vivo phosphorylation site in CK2a. The effect of its phosphorylation is unclear.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: EDL-pY-DYI

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1184.13 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: CK2a1 - pY255 phosphosite-specific antibody (Cat. No.: AB-PK582)

Scientific Background: CK2a1 (CSNK2A1) is a protein-serine/threonine kinase of the Other group and CK2 family. CK2a1 is activated by the CK2-beta regulatory subunit and also by binding p38a MAPK. CK2 is potently inhibited by heparin. It is involved in various cellular processes, such as cell cycle control, apoptosis, transcription, and viral infection. It can phosphorylate human p53 protein a tS392 with presence of UV irradiation, which may be a potential mechanism for p53 activation by UV irradiation. It also phosphorylates the caspases CASP9 and CASP2, and hence negatively regulates apoptosis. CK2a1 levels are often up-regulated by 2-fold in expression in many human tumours.